Search
  • Search
Germany: Tenders/Helmholtz-Zentrum für Infektionsforschung GmbH/Preclinical Drug Discovery Services

  1. Competition notice published

    Feb 28, 2024 10:00 PMFebruary 28, 2024 10:00 PM

  2. Supplier selection

    May 6, 2024 12:00 AMMay 6, 2024 12:00 AM

  3. Result notice published

    May 12, 2024 8:00 PMMay 12, 2024 8:00 PM

Brief

Preclinical Drug Discovery Services

Awarded

The competition has ended and a winner has been selected.

Deadline
May 12, 2024Expired
Award
Quality 45%
Procedure
OpenSingle stage
Agreement
Framework agreement
Estimated value
€500Kover 4 years

Brief

Non-GLP preclinical small molecule drug discovery services of the following kind and quantity, to be provided under Master Service Agreement.

Forsknings- og analyselaboratorier

Result

TED
  • Number of bids
    1
  • Contract value
    Not stated
  • Maximum framework agreement valueUp to €0

Custom Assessment Criteria

  • Get answers to your bid/no-bid criteria

    Set them up once and Cobrief answers them in every tender

Will you bid?

The agent sets up the bid and writes the first draft. Free for 14 days.

Award Criteria

  • Description

    Price - siehe Vergabeunterlagen

    Source

    No source found in the documents. Check the weight against the tender documents.

  • Description

    Quality - siehe Vergabeunterlagen

    Source

    No source found in the documents. Check the weight against the tender documents.

Previous winners

  • Who are you up against?

    The suppliers who have won similar contracts at Helmholtz-Zentrum für Infektionsforschung GmbH

From the notice

  • Non-GLP preclinical small molecule drug discovery services of the following kind and quantity, to be provided under Master Service Agreement.Main features of the procedureRequests to participate must be submitted electronically in text form (Section 126b BGB) via the procurement portal. Further information can be found on the homepage of the procurement portal. All communication between the contracting authority and the candidates will take place exclusively via the procurement portal. The contracting authority shall make all questions and answers available on the procurement portal in anonymized form. The formation of applicant/bidder consortia is only possible until the submission of the tender. The information on the composition of the bidding consortium is generally binding.

  • Contact

    einkauf@helmholtz-hzi.de
  • Type
    Result · Framework agreement
  • Location
    Braunschweig, Kreisfreie Stadt
  • Main code
    Research and development services and related consultancy services
    73000000
  • 73111000Research laboratory services

Similar active competitions

  • Helmholtz-Zentrum für Infektionsforschung GmbH

    Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester

    Non-Clinical Toxicology and safety assessment of a small molecule

    Helmholtz-Zentrum für Infektionsforschung GmbH seeks services under a framework agreement to conduct a nonclinical toxicology and safety assessment programme for a small-molecule drug candidate, with delivery in Braunschweig, Germany. The work includes assessing safety after intravenous infusion, with particular focus on renal function and toxicity, and a dermal toxicology programme to support a potential topical semisolid formulation; the dermal work is subject to a Go/No-Go decision. The programme must meet applicable regulatory requirements and produce documentation suitable for submissions in the EU and US, supporting first-in-human trials and further clinical development. The project manager must have C1-level German or English, and applicable studies must comply with OECD GLP or equivalent principles, supported by GLP compliance evidence. Evaluation gives 75% weight to quality (project execution concept 45%, capability concept 30%) and 25% to price.

    Framework agreement
    Dec 7, 2026(31 days)

  • Charité - Universitätsmedizin Berlin

    Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester

    Produktion von Lentivirus in GMP-Qualität

    Die Charité - Universitätsmedizin Berlin benötigt Dienstleistungen zur Produktion von Lentivirus in GMP-Qualität zur Transduktion humaner Zellen, inklusive Dokumentation und einer Stabilitätsstudie, für 76 Monate in Berlin. Miltenyi Biotec B.V. & Co.KG hat heute einen ähnlichen Vertrag. Die Vergabe erfolgt auf Basis des niedrigsten Preises (50 %) und eines Umsetzungskonzepts (50 %). Als Qualifikationsanforderungen sind drei Unternehmensreferenzen aus den letzten drei Jahren über vergleichbare Aufträge zur Herstellung klinischer Vektoren in Deutschland, inklusive regulatorischer Einreichungen bei deutschen Behörden, sowie mindestens 10 Einreichungen von „regulatory support files“ beim Paul-Ehrlich-Institut für Vektoren, die in der Anlage hergestellt werden, in der das Lentivirus produziert wird, nachzuweisen.

    Competition
    Nov 17, 2026(11 days)

  • Universitätsklinikum Heidelberg

    Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester

    Markterkundung zur GMP-Herstellung eines Multi-Peptid-Prüfpräparats (IMP) für eine klinische Phase-I-Studie

    Das Universitätsklinikum Heidelberg plant die Beschaffung von Dienstleistungen zur GMP-Herstellung eines Multi-Peptid-Prüfpräparats (IMP) für eine klinische Phase-I-Studie. Gesucht werden Auftragsentwicklungs- und Herstellungsorganisationen (CDMOs) oder akademische GMP-Einheiten, die die Entwicklung, GMP-konforme Herstellung, Qualitätskontrolle, Freigabe, Dokumentation und Distribution des IMPs übernehmen können. Lieferanten können Feedback geben, indem sie sich an der Markterkundung beteiligen, um die technische Machbarkeit, Vorlaufzeiten und Kostenspannen zu ermitteln.

    Planning
    Nov 10, 2026(4 days)